Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akero Therapeutics, Inc.AKRO · Entity 71984 | Director | June 01, 2021 | June 03, 2021 |
| Disc Medicine, Inc.IRON · Entity 2273 | Director | September 11, 2026 | September 15, 2026 |
| Editas Medicine, Inc.EDIT · Entity 5502 | Director | June 15, 2017 | June 19, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akero Therapeutics, Inc.
Report date June 01, 2021 · Filed June 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2021-06-01 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2021-06-01 · Sale · Disposed 16,544 · Balance 0 F1: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2: The shares reported herein give effect to the pro rata distribution of shares by Atlas Venture Fund XI, L.P. ("AVF XI") and Atlas Venture Opportunity Fund I, L.P. ("AVOF") for no additional consideration to their respective limited and general partners, including Atlas Venture Associates XI, LP ("AVA XI LP") and Atlas Venture Associates Opportunity I, LLC ("AVAO LP"). As the distributions of such shares constituted only a change in the form of the Reporting Person's indirect ownership in such shares, the Reporting Person was not required to report these distributions pursuant to Section 16. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.73 to $26.67 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: These shares are owned directly by AVA XI LP. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2021-06-01 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2021-06-01 · Sale · Disposed 945 · Balance 0 F1: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2: The shares reported herein give effect to the pro rata distribution of shares by Atlas Venture Fund XI, L.P. ("AVF XI") and Atlas Venture Opportunity Fund I, L.P. ("AVOF") for no additional consideration to their respective limited and general partners, including Atlas Venture Associates XI, LP ("AVA XI LP") and Atlas Venture Associates Opportunity I, LLC ("AVAO LP"). As the distributions of such shares constituted only a change in the form of the Reporting Person's indirect ownership in such shares, the Reporting Person was not required to report these distributions pursuant to Section 16. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.73 to $26.67 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5: These shares are owned directly by AVAO LP. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of the securities, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,963,529 |
Reported balance
Holding disclosure · report date 2021-06-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,963,529 F2: The shares reported herein give effect to the pro rata distribution of shares by Atlas Venture Fund XI, L.P. ("AVF XI") and Atlas Venture Opportunity Fund I, L.P. ("AVOF") for no additional consideration to their respective limited and general partners, including Atlas Venture Associates XI, LP ("AVA XI LP") and Atlas Venture Associates Opportunity I, LLC ("AVAO LP"). As the distributions of such shares constituted only a change in the form of the Reporting Person's indirect ownership in such shares, the Reporting Person was not required to report these distributions pursuant to Section 16. F6: These shares are owned directly by AVF XI. AVA XI LP is the general partner of AVF XI. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 268,722 |
Reported balance
Holding disclosure · report date 2021-06-01 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 268,722 F2: The shares reported herein give effect to the pro rata distribution of shares by Atlas Venture Fund XI, L.P. ("AVF XI") and Atlas Venture Opportunity Fund I, L.P. ("AVOF") for no additional consideration to their respective limited and general partners, including Atlas Venture Associates XI, LP ("AVA XI LP") and Atlas Venture Associates Opportunity I, LLC ("AVAO LP"). As the distributions of such shares constituted only a change in the form of the Reporting Person's indirect ownership in such shares, the Reporting Person was not required to report these distributions pursuant to Section 16. F7: These shares are owned directly by AVOF. AVAO LP is the general partner of AVOF. AVAO LLC is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of the securities held by AVOF, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were sold pursuant to a Rule 10b5-1 trading plan.
F2: The shares reported herein give effect to the pro rata distribution of shares by Atlas Venture Fund XI, L.P. ("AVF XI") and Atlas Venture Opportunity Fund I, L.P. ("AVOF") for no additional consideration to their respective limited and general partners, including Atlas Venture Associates XI, LP ("AVA XI LP") and Atlas Venture Associates Opportunity I, LLC ("AVAO LP"). As the distributions of such shares constituted only a change in the form of the Reporting Person's indirect ownership in such shares, the Reporting Person was not required to report these distributions pursuant to Section 16.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.73 to $26.67 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: These shares are owned directly by AVA XI LP. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities, except to the extent of his pecuniary interest therein, if any.
F5: These shares are owned directly by AVAO LP. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of the securities, except to the extent of his pecuniary interest therein, if any.
F6: These shares are owned directly by AVF XI. AVA XI LP is the general partner of AVF XI. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of his pecuniary interest therein, if any.
F7: These shares are owned directly by AVOF. AVAO LP is the general partner of AVOF. AVAO LLC is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of the securities held by AVOF, except to the extent of his pecuniary interest therein, if any.
Disc Medicine, Inc.
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-11 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-11 · Exercise / conversion · Acquired 7,136 · Balance 7,136 Row 2 · 2026-09-11 · Exercise / conversion · Acquired 10,000 · Balance 17,136 Row 3 · 2026-09-11 · Exercise / conversion · Acquired 10,000 · Balance 27,136 Row 4 · 2026-09-11 · Sale · Disposed 27,136 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.10 to $70.37 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.69 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-11 · Exercise / conversion · Disposed 7,136 · Balance 0 F5: Fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.85 · Expires 2034-06-11 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-11 · Exercise / conversion · Disposed 10,000 · Balance 0 F5: Fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.86 · Expires 2035-06-10 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-11 · Exercise / conversion · Disposed 10,000 · Balance 0 F5: Fully vested and exercisable. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 318,866 |
Reported balance
Holding disclosure · report date 2026-09-11 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 318,866 F2: These shares are held by Atlas Venture Opportunity Fund I, L.P. ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, L.P. ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 312,230 |
Reported balance
Holding disclosure · report date 2026-09-11 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 312,230 F3: These shares are held by Atlas Venture Opportunity Fund II, L.P. ("Opportunity II"). The general partner of Opportunity II is Atlas Venture Associates Opportunity II, L.P. ("Associates II"). Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims beneficial ownership of such securities held by Opportunity II, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 13,427 |
Reported balance
Holding disclosure · report date 2026-09-11 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 13,427 F4: These shares are held by Atlas Venture Fund XII, L.P. ("Atlas XII"). The general partner of Atlas XII is Atlas Venture Associates XII, L.P. ("Associates XII"). Atlas Venture Associates XII, LLC ("Associates XII LLC") is the general partner of Associates XII. The Reporting Person is a member of Associates XII LLC and disclaims beneficial ownership of such securities held by Atlas XII, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.10 to $70.37 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: These shares are held by Atlas Venture Opportunity Fund I, L.P. ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, L.P. ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any.
F3: These shares are held by Atlas Venture Opportunity Fund II, L.P. ("Opportunity II"). The general partner of Opportunity II is Atlas Venture Associates Opportunity II, L.P. ("Associates II"). Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims beneficial ownership of such securities held by Opportunity II, except to the extent of his pecuniary interest therein, if any.
F4: These shares are held by Atlas Venture Fund XII, L.P. ("Atlas XII"). The general partner of Atlas XII is Atlas Venture Associates XII, L.P. ("Associates XII"). Atlas Venture Associates XII, LLC ("Associates XII LLC") is the general partner of Associates XII. The Reporting Person is a member of Associates XII LLC and disclaims beneficial ownership of such securities held by Atlas XII, except to the extent of his pecuniary interest therein, if any.
F5: Fully vested and exercisable.
Editas Medicine, Inc.
Report date June 15, 2017 · Filed June 19, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.63 · Expires 2027-06-14 | Direct | 11,538 |
Reported balance
After 2017-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-15 · Grant · Acquired 11,538 · Balance 11,538 F1: This option was granted on June 15, 2017 and is scheduled to vest in full on June 15, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 15, 2017 and is scheduled to vest in full on June 15, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 15, 2026 20:30 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $50.86 | $0.00 |
DisclosureSEC source: 0001591747-26-000007 · form4-09152026_040930.xml · derivative · entry 10 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2035-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 20:30 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $38.85 | $0.00 |
DisclosureSEC source: 0001591747-26-000007 · form4-09152026_040930.xml · derivative · entry 9 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2034-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 20:30 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,136 | $0.00 Strike: $45.69 | $0.00 |
DisclosureSEC source: 0001591747-26-000007 · form4-09152026_040930.xml · derivative · entry 8 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,136 shares Expires 2033-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 20:30 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 27,136 | $70.11 | $1,902,504.96 |
DisclosureSEC source: 0001591747-26-000007 · form4-09152026_040930.xml · nonDerivative · entry 4 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.10 to $70.37 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 20:30 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionCommon Stock | 10,000 | $50.86 | $508,600.00 |
DisclosureSEC source: 0001591747-26-000007 · form4-09152026_040930.xml · nonDerivative · entry 3 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 20:30 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionCommon Stock | 10,000 | $38.85 | $388,500.00 |
DisclosureSEC source: 0001591747-26-000007 · form4-09152026_040930.xml · nonDerivative · entry 2 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 20:30 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionCommon Stock | 7,136 | $45.69 | $326,043.84 |
DisclosureSEC source: 0001591747-26-000007 · form4-09152026_040930.xml · nonDerivative · entry 1 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 04, 2026 Filed Sep 9, 2026 20:23 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 18 | $79.96 | $1,439.28 |
DisclosureSEC source: 0001591747-26-000005 · form4-09092026_080927.xml · nonDerivative · entry 3 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 13,427 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.95 to $79.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: These shares are held by Atlas Venture Fund XII, L.P. ("Atlas XII"). The general partner of Atlas XII is Atlas Venture Associates XII, L.P. ("Associates XII"). Atlas Venture Associates XII, LLC ("Associates XII LLC") is the general partner of Associates XII. The Reporting Person is a member of Associates XII LLC and disclaims beneficial ownership of such securities held by Atlas XII, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 04, 2026 Filed Sep 9, 2026 20:23 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 759 | $79.96 | $60,689.64 |
DisclosureSEC source: 0001591747-26-000005 · form4-09092026_080927.xml · nonDerivative · entry 2 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 312,230 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.95 to $79.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund II, L.P. ("Opportunity II"). The general partner of Opportunity II is Atlas Venture Associates Opportunity II, L.P. ("Associates II"). Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims beneficial ownership of such securities held by Opportunity II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 04, 2026 Filed Sep 9, 2026 20:23 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 912 | $79.96 | $72,923.52 |
DisclosureSEC source: 0001591747-26-000005 · form4-09092026_080927.xml · nonDerivative · entry 1 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 318,866 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.95 to $79.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund I, L.P. ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, L.P. ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 03, 2026 Filed Sep 3, 2026 21:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 54 | $79.98 | $4,318.92 |
DisclosureSEC source: 0001591747-26-000002 · form4-09032026_090939.xml · nonDerivative · entry 12 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 13,445 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.95 to $80.28 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: These shares are held by Atlas Venture Fund XII, L.P. ("Atlas XII"). The general partner of Atlas XII is Atlas Venture Associates XII, L.P. ("Associates XII"). Atlas Venture Associates XII, LLC ("Associates XII LLC") is the general partner of Associates XII. The Reporting Person is a member of Associates XII LLC and disclaims beneficial ownership of such securities held by Atlas XII, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 03, 2026 Filed Sep 3, 2026 21:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 2,339 | $79.98 | $187,073.22 |
DisclosureSEC source: 0001591747-26-000002 · form4-09032026_090939.xml · nonDerivative · entry 11 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 312,989 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.95 to $80.28 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund II, L.P. ("Opportunity II"). The general partner of Opportunity II is Atlas Venture Associates Opportunity II, L.P. ("Associates II"). Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims beneficial ownership of such securities held by Opportunity II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 03, 2026 Filed Sep 3, 2026 21:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 2,810 | $79.98 | $224,743.80 |
DisclosureSEC source: 0001591747-26-000002 · form4-09032026_090939.xml · nonDerivative · entry 10 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 319,778 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.95 to $80.28 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund I, L.P. ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, L.P. ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 21:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 2 | $80.98 | $161.96 |
DisclosureSEC source: 0001591747-26-000002 · form4-09032026_090939.xml · nonDerivative · entry 9 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 13,499 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.9677 to $81.0079 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: These shares are held by Atlas Venture Fund XII, L.P. ("Atlas XII"). The general partner of Atlas XII is Atlas Venture Associates XII, L.P. ("Associates XII"). Atlas Venture Associates XII, LLC ("Associates XII LLC") is the general partner of Associates XII. The Reporting Person is a member of Associates XII LLC and disclaims beneficial ownership of such securities held by Atlas XII, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 21:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 9 | $80.98 | $728.82 |
DisclosureSEC source: 0001591747-26-000002 · form4-09032026_090939.xml · nonDerivative · entry 8 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 315,328 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.9677 to $81.0079 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund II, L.P. ("Opportunity II"). The general partner of Opportunity II is Atlas Venture Associates Opportunity II, L.P. ("Associates II"). Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims beneficial ownership of such securities held by Opportunity II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 21:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 10 | $80.98 | $809.80 |
DisclosureSEC source: 0001591747-26-000002 · form4-09032026_090939.xml · nonDerivative · entry 7 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 322,588 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.9677 to $81.0079 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund I, L.P. ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, L.P. ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 21:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 511 | $80.17 | $40,966.87 |
DisclosureSEC source: 0001591747-26-000002 · form4-09032026_090939.xml · nonDerivative · entry 6 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 13,501 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.95 to $80.9421 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: These shares are held by Atlas Venture Fund XII, L.P. ("Atlas XII"). The general partner of Atlas XII is Atlas Venture Associates XII, L.P. ("Associates XII"). Atlas Venture Associates XII, LLC ("Associates XII LLC") is the general partner of Associates XII. The Reporting Person is a member of Associates XII LLC and disclaims beneficial ownership of such securities held by Atlas XII, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 21:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 22,090 | $80.17 | $1,770,955.30 |
DisclosureSEC source: 0001591747-26-000002 · form4-09032026_090939.xml · nonDerivative · entry 5 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 315,337 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.95 to $80.9421 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund II, L.P. ("Opportunity II"). The general partner of Opportunity II is Atlas Venture Associates Opportunity II, L.P. ("Associates II"). Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims beneficial ownership of such securities held by Opportunity II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 21:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 26,542 | $80.17 | $2,127,872.14 |
DisclosureSEC source: 0001591747-26-000002 · form4-09032026_090939.xml · nonDerivative · entry 4 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 322,598 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.95 to $80.9421 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund I, L.P. ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, L.P. ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 21:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 1 | $79.95 | $79.95 |
DisclosureSEC source: 0001591747-26-000002 · form4-09032026_090939.xml · nonDerivative · entry 3 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 14,012 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026. F4 · ownership.nature: These shares are held by Atlas Venture Fund XII, L.P. ("Atlas XII"). The general partner of Atlas XII is Atlas Venture Associates XII, L.P. ("Associates XII"). Atlas Venture Associates XII, LLC ("Associates XII LLC") is the general partner of Associates XII. The Reporting Person is a member of Associates XII LLC and disclaims beneficial ownership of such securities held by Atlas XII, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 21:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 58 | $79.95 | $4,637.10 |
DisclosureSEC source: 0001591747-26-000002 · form4-09032026_090939.xml · nonDerivative · entry 2 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 337,427 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026. F3 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund II, L.P. ("Opportunity II"). The general partner of Opportunity II is Atlas Venture Associates Opportunity II, L.P. ("Associates II"). Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims beneficial ownership of such securities held by Opportunity II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 21:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 70 | $79.95 | $5,596.50 |
DisclosureSEC source: 0001591747-26-000002 · form4-09032026_090939.xml · nonDerivative · entry 1 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 349,140 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026. F2 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund I, L.P. ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, L.P. ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 20:56 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 6,212 | $0.00 Strike: $70.79 | $0.00 |
DisclosureSEC source: 0001193125-26-279705 · ownership.xml · derivative · entry 1 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,212 Underlying: Common Stock · 6,212 shares Expires 2036-06-17 F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. F2 · ownership.direct: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 17, 2025 Filed Dec 18, 2025 23:14 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 148 | $91.47 | $13,537.56 |
DisclosureSEC source: 0001591747-25-000008 · form4-12182025_111250.xml · nonDerivative · entry 3 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 14,013 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.2501 to $91.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote. F4 · ownership.nature: These shares are held by Atlas Venture Fund XII, L.P. ("Atlas XII"). The general partner of Atlas XII is Atlas Venture Associates XII, L.P. ("Associates XII"). Atlas Venture Associates XII, LLC ("Associates XII LLC") is the general partner of Associates XII. The Reporting Person is a member of Associates XII LLC and disclaims beneficial ownership of such securities held by Atlas XII, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 17, 2025 Filed Dec 18, 2025 23:14 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 213 | $91.47 | $19,483.11 |
DisclosureSEC source: 0001591747-25-000008 · form4-12182025_111250.xml · nonDerivative · entry 2 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 337,485 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.2501 to $91.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote. F3 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund II, LP ("Opportunity II"). The general partner of Opportunity II is Atlas Venture Associates Opportunity II, LP ("Associates II"). Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims beneficial ownership of such securities held by Opportunity II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 17, 2025 Filed Dec 18, 2025 23:14 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 393 | $91.47 | $35,947.71 |
DisclosureSEC source: 0001591747-25-000008 · form4-12182025_111250.xml · nonDerivative · entry 1 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 349,210 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.2501 to $91.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote. F2 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 16, 2025 Filed Dec 17, 2025 02:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 14,359 | $91.24 | $1,310,115.16 |
DisclosureSEC source: 0001104659-25-121740 · tm2530644-8_4seq1.xml · nonDerivative · entry 20 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 14,161 F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.00 to $91.705 inclusive. F6 · ownership.nature: These shares are held by Atlas Venture Fund XII, L.P. ("Atlas XII"). The general partner of Atlas XII is Atlas Venture Associates XII, L.P. ("Associates XII"). Atlas Venture Associates XII, LLC ("Associates XII LLC") is the general partner of Associates XII. The Reporting Person is a member of Associates XII LLC and disclaims beneficial ownership of such securities held by Atlas XII, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 16, 2025 Filed Dec 17, 2025 02:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 18,666 | $91.24 | $1,703,085.84 |
DisclosureSEC source: 0001104659-25-121740 · tm2530644-8_4seq1.xml · nonDerivative · entry 19 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 337,698 F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.00 to $91.705 inclusive. F5 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund II, LP ("Opportunity II"). The general partner of Opportunity II is Atlas Venture Associates Opportunity II, LP ("Associates II"). Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims beneficial ownership of such securities held by Opportunity II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 16, 2025 Filed Dec 17, 2025 02:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 35,898 | $91.24 | $3,275,333.52 |
DisclosureSEC source: 0001104659-25-121740 · tm2530644-8_4seq1.xml · nonDerivative · entry 18 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 349,603 F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.00 to $91.705 inclusive. F2 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 02:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0001104659-25-121740 · tm2530644-8_4seq1.xml · derivative · entry 21 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2032-12-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully Vested. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 02:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 7,000 | $91.87 | $643,090.00 |
DisclosureSEC source: 0001104659-25-121740 · tm2530644-8_4seq1.xml · nonDerivative · entry 17 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.79 to $91.95 inclusive. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 02:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionCommon Stock | 7,000 | $13.50 | $94,500.00 |
DisclosureSEC source: 0001104659-25-121740 · tm2530644-8_4seq1.xml · nonDerivative · entry 16 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 02:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 1,572 | $92.01 | $144,639.72 |
DisclosureSEC source: 0001104659-25-121740 · tm2530644-8_4seq1.xml · nonDerivative · entry 15 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 28,520 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.48 inclusive. F6 · ownership.nature: These shares are held by Atlas Venture Fund XII, L.P. ("Atlas XII"). The general partner of Atlas XII is Atlas Venture Associates XII, L.P. ("Associates XII"). Atlas Venture Associates XII, LLC ("Associates XII LLC") is the general partner of Associates XII. The Reporting Person is a member of Associates XII LLC and disclaims beneficial ownership of such securities held by Atlas XII, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 02:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 11,427 | $91.18 | $1,041,913.86 |
DisclosureSEC source: 0001104659-25-121740 · tm2530644-8_4seq1.xml · nonDerivative · entry 14 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 30,092 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.00 to $91.99 inclusive. F6 · ownership.nature: These shares are held by Atlas Venture Fund XII, L.P. ("Atlas XII"). The general partner of Atlas XII is Atlas Venture Associates XII, L.P. ("Associates XII"). Atlas Venture Associates XII, LLC ("Associates XII LLC") is the general partner of Associates XII. The Reporting Person is a member of Associates XII LLC and disclaims beneficial ownership of such securities held by Atlas XII, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 02:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 2,049 | $92.01 | $188,528.49 |
DisclosureSEC source: 0001104659-25-121740 · tm2530644-8_4seq1.xml · nonDerivative · entry 13 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 356,364 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.48 inclusive. F5 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund II, LP ("Opportunity II"). The general partner of Opportunity II is Atlas Venture Associates Opportunity II, LP ("Associates II"). Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims beneficial ownership of such securities held by Opportunity II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 02:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 14,811 | $91.18 | $1,350,466.98 |
DisclosureSEC source: 0001104659-25-121740 · tm2530644-8_4seq1.xml · nonDerivative · entry 12 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 358,413 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.00 to $91.99 inclusive. F5 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund II, LP ("Opportunity II"). The general partner of Opportunity II is Atlas Venture Associates Opportunity II, LP ("Associates II"). Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims beneficial ownership of such securities held by Opportunity II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 02:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 3,921 | $92.01 | $360,771.21 |
DisclosureSEC source: 0001104659-25-121740 · tm2530644-8_4seq1.xml · nonDerivative · entry 11 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 385,501 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.48 inclusive. F2 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 02:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 28,913 | $91.18 | $2,636,287.34 |
DisclosureSEC source: 0001104659-25-121740 · tm2530644-8_4seq1.xml · nonDerivative · entry 10 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 389,422 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.00 to $91.99 inclusive. F2 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 02:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 1,371 | $93.80 | $128,599.80 |
DisclosureSEC source: 0001104659-25-121740 · tm2530644-8_4seq1.xml · nonDerivative · entry 9 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 41,519 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.52 to $94.255 inclusive. F6 · ownership.nature: These shares are held by Atlas Venture Fund XII, L.P. ("Atlas XII"). The general partner of Atlas XII is Atlas Venture Associates XII, L.P. ("Associates XII"). Atlas Venture Associates XII, LLC ("Associates XII LLC") is the general partner of Associates XII. The Reporting Person is a member of Associates XII LLC and disclaims beneficial ownership of such securities held by Atlas XII, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 02:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 1,540 | $92.58 | $142,573.20 |
DisclosureSEC source: 0001104659-25-121740 · tm2530644-8_4seq1.xml · nonDerivative · entry 8 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 42,890 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.52 to $93.3796 inclusive. F6 · ownership.nature: These shares are held by Atlas Venture Fund XII, L.P. ("Atlas XII"). The general partner of Atlas XII is Atlas Venture Associates XII, L.P. ("Associates XII"). Atlas Venture Associates XII, LLC ("Associates XII LLC") is the general partner of Associates XII. The Reporting Person is a member of Associates XII LLC and disclaims beneficial ownership of such securities held by Atlas XII, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 02:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 6,570 | $92.05 | $604,768.50 |
DisclosureSEC source: 0001104659-25-121740 · tm2530644-8_4seq1.xml · nonDerivative · entry 7 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 44,430 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.5289 to $92.4325 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3), (4), (7), (8), (9) and (10). F6 · ownership.nature: These shares are held by Atlas Venture Fund XII, L.P. ("Atlas XII"). The general partner of Atlas XII is Atlas Venture Associates XII, L.P. ("Associates XII"). Atlas Venture Associates XII, LLC ("Associates XII LLC") is the general partner of Associates XII. The Reporting Person is a member of Associates XII LLC and disclaims beneficial ownership of such securities held by Atlas XII, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 02:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 1,793 | $93.80 | $168,183.40 |
DisclosureSEC source: 0001104659-25-121740 · tm2530644-8_4seq1.xml · nonDerivative · entry 6 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 373,224 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.52 to $94.255 inclusive. F5 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund II, LP ("Opportunity II"). The general partner of Opportunity II is Atlas Venture Associates Opportunity II, LP ("Associates II"). Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims beneficial ownership of such securities held by Opportunity II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 02:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 2,005 | $92.58 | $185,622.90 |
DisclosureSEC source: 0001104659-25-121740 · tm2530644-8_4seq1.xml · nonDerivative · entry 5 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 375,017 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.52 to $93.3796 inclusive. F5 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund II, LP ("Opportunity II"). The general partner of Opportunity II is Atlas Venture Associates Opportunity II, LP ("Associates II"). Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims beneficial ownership of such securities held by Opportunity II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 02:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 8,527 | $92.05 | $784,910.35 |
DisclosureSEC source: 0001104659-25-121740 · tm2530644-8_4seq1.xml · nonDerivative · entry 4 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 377,022 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.5289 to $92.4325 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3), (4), (7), (8), (9) and (10). F5 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund II, LP ("Opportunity II"). The general partner of Opportunity II is Atlas Venture Associates Opportunity II, LP ("Associates II"). Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims beneficial ownership of such securities held by Opportunity II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 02:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 3,446 | $93.80 | $323,234.80 |
DisclosureSEC source: 0001104659-25-121740 · tm2530644-8_4seq1.xml · nonDerivative · entry 3 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 418,335 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.52 to $94.255 inclusive. F2 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 02:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 3,852 | $92.58 | $356,618.16 |
DisclosureSEC source: 0001104659-25-121740 · tm2530644-8_4seq1.xml · nonDerivative · entry 2 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 421,781 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.52 to $93.3796 inclusive. F2 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 02:43 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 16,403 | $92.05 | $1,509,896.15 |
DisclosureSEC source: 0001104659-25-121740 · tm2530644-8_4seq1.xml · nonDerivative · entry 1 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 425,633 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.5289 to $92.4325 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3), (4), (7), (8), (9) and (10). F2 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 17, 2025 Filed Oct 17, 2025 20:41 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 450 | $91.88 | $41,346.00 |
DisclosureSEC source: 0001591747-25-000006 · form4-10172025_081039.xml · nonDerivative · entry 17 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 385,549 F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.37 to $92.15 inclusive. F5 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund II, LP ("Opportunity II"). The general partner of Opportunity II is Atlas Venture Associates Opportunity II, LP ("Associates II"). Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims beneficial ownership of such securities held by Opportunity II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 17, 2025 Filed Oct 17, 2025 20:41 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 450 | $91.88 | $41,346.00 |
DisclosureSEC source: 0001591747-25-000006 · form4-10172025_081039.xml · nonDerivative · entry 16 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 442,036 F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.37 to $92.15 inclusive. F2 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 17, 2025 Filed Oct 17, 2025 20:41 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 10,095 | $90.66 | $915,212.70 |
DisclosureSEC source: 0001591747-25-000006 · form4-10172025_081039.xml · nonDerivative · entry 15 Bitterman Kevin · CIK 0001591747 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 385,999 F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.25 to $91.24 inclusive. F5 · ownership.nature: These shares are held by Atlas Venture Opportunity Fund II, LP ("Opportunity II"). The general partner of Opportunity II is Atlas Venture Associates Opportunity II, LP ("Associates II"). Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims beneficial ownership of such securities held by Opportunity II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.